Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

32.540
-1.380-4.07%
Volume:6.65M
Turnover:222.02M
Market Cap:197.32B
PE:29.89
High:34.560
Open:34.040
Low:32.360
Close:33.920
52wk High:43.587
52wk Low:27.658
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:1.23
T/O Rate:0.11%
Dividend:0.49
Dividend Rate:1.49%
EPS(LYR):1.089
ROE:19.40%
ROA:9.08%
PB:4.46
PE(LYR):29.89
PS:10.60

Loading ...

Hansoh Pharmaceutical - Hs-10374 Meets Co-Primary Endpoints in Phase Iii Plaque Psoriasis Trial

THOMSON REUTERS
·
Sep 21

Movement Alert|HANSOH PHARMA Rises 3.09% in Regular Trading, New Drug HS-20197 Approved for Clinical Trials Targeting Solid Tumors

Market Focus
·
Sep 18

Hansoh Pharmaceutical Group Stock Climbs 1.0% in Hong Kong

Dow Jones
·
Sep 17

Hansoh Pharma Gets China Approval for Solid Tumor Drug Trials

MT Newswires Live
·
Sep 16

Hansoh Pharmaceutical - Hs-20197 for Injection Receives Clinical Trial Approval from Nmpa of China

THOMSON REUTERS
·
Sep 16

UBS Highlights Encouraging Phase 3 Data for Hansoh Pharma's Ris-Rez in Relapsed Small Cell Lung Cancer, Maintains "Buy" Rating

Stock News
·
Sep 15

Roche, GSK's Lung-Cancer Drug Candidates Show Promise in China

Dow Jones
·
Sep 14

AI Concerns, Oil Bills Blunt Asian Stock Markets

MT Newswires Live
·
Sep 14

Hansoh Pharma Reports 81.5% Response Rate in Phase Ib HS-10370 Combo Trial in First-Line KRAS G12C NSCLC

Reuters
·
Sep 14

Hansoh Pharmaceutical Group Stock Rises 5.1% in Hong Kong

Dow Jones
·
Sep 14

GSK Gains After Positive Results for Two Lung Cancer Drugs

Reuters
·
Sep 14

JPMorgan Highlights Encouraging Lung Cancer Data for Hansoh Pharma's B7-H3 ADC, Reaffirms Overweight Rating

Stock News
·
Sep 14

HK Stock Alert: Hansoh Pharma Climbs Nearly 4%; Drug Trial Shows Median Survival of 18.5 Months

Stock News
·
Sep 14

Movement Alert|HANSOH PHARMA Rises 3.12% in Regular Trading, B7-H3 ADC Phase III Data Reveals Record-Breaking Survival Benefit in Small Cell Lung Cancer

Market Focus
·
Sep 14

Hansoh Pharma Says Phase 3 Artemis-008 Study Shows Overall Survival Gain for Risvutatug Rezetecan in Relapsed SCLC

Reuters
·
Sep 13

Hansoh Pharmaceutical Says Risvutatug Rezetecan Injection Included in NMPA Priority Review

Reuters
·
Sep 11

Hansoh Pharma’s Risvutatug Rezetecan for Small-Cell Lung Cancer Enters NMPA Priority Review

Bulletin Express
·
Sep 11

Hansoh Pharma's Investigational Therapy for Small Cell Lung Cancer Granted Priority Review by Chinese Regulator

Stock News
·
Sep 11

Hansoh Pharmaceutical Group Stock Slides 1.9% in Hong Kong

Dow Jones
·
Sep 11

Hansoh Pharma Says NMPA Grants Priority Review for HS-20093 in Small Cell Lung Cancer

Reuters
·
Sep 11